Zoetis (ZTS) Receives Positive Opinion from CVMP for Portela®

Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy right now. Zoetis Inc. (NYSE:ZTS) announced on September 12 the adoption of a positive opinion by the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) regarding recommending the granting of marketing authorization for Portela (relfovetmab).

Is Zoetis a Unique Dividend Play in the Pharma Space for 2025?

Portela is a new monoclonal antibody (mAb) therapy intended to alleviate pain associated with osteoarthritis (OA) in cats. Zoetis Inc. (NYSE:ZTS) reported that if approved, Portela would be the first long-acting anti-nerve growth factor (NGF) mAb therapy for cats.

It is designed to offer “three months of osteoarthritis (OA) pain relief with a single injection,” as it targets NGF, a key mediator of OA pain.

Management further reported that the CVMP recommended the grant of marketing authorization based on a positive benefit-risk balance of the safety and efficacy data submitted.

Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health.

Its operations are divided into the United States and International segments. Each segment boasts a diversified product portfolio, including vaccines, parasiticides, pain and sedation, animal health diagnostics, and more.

The company markets its products in around 45 countries across the globe and specializes in products across eight core species: companion animals (dogs, cats, and horses), cattle, swine, livestock (sheep and fish), and poultry.

While we acknowledge the potential of ZTS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZTS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.